Search

Background Impaired motor functions after stroke are common and negatively affect patients' activities of daily living and quality of life. In particular, hand motor function is essential for daily activities, but often returns slowly and incompletely after stroke. However, few data are available on the long-term dynamics of motor recovery and self-reported health status after stroke. The Interdisciplinary Platform for Rehabilitation Research and Innovative Care of Stroke Patients (IMPROVE) project aims to address this knowledge gap by studying the clinical course of recovery after inpatient rehabilitation. Methods In this prospective observational longitudinal multicenter study, patients were included towards the end of inpatient rehabilitation after ischemic or hemorrhagic stroke. Follow-up examination was performed at three, six, and twelve months after enrollment. Motor function was assessed by the Upper Extremity Fugl-Meyer Assessment (FMA), grip and pinch strength, and the nine-hole peg test. In addition, Patient-Reported Outcomes Measurement Information System 10-Question Short Form (PROMIS-10) was included. Linear mixed effect models were fitted to analyze change over time. To study determinants of hand motor function, patients with impaired hand function at baseline were grouped into improvers and non-improvers according to hand motor function after twelve months. Results A total of 176 patients were included in the analysis. Improvement in all motor function scores and PROMIS-10 was shown up to 1 year after inpatient rehabilitation. FMA scores improved by an estimate of 5.0 (3.7–6.4) points per year. In addition, patient-reported outcome measures increased by 2.5 (1.4–3.6) and 2.4 (1.4–3.4) per year in the physical and mental domain of PROMIS-10. In the subgroup analysis non-improvers showed to be more often female (15% vs. 55%, p = 0.0155) and scored lower in the Montreal Cognitive Assessment (25 [23–27] vs. 22 [20.5–24], p = 0.0252). Conclusions Continuous improvement in motor function and self-reported health status is observed up to 1 year after inpatient stroke rehabilitation. Demographic and clinical parameters associated with these improvements need further investigation. These results may contribute to the further development of the post-inpatient phase of stroke rehabilitation. Trial registration: The trial is registered at ClinicalTrials.gov (NCT04119479).

The halogenido stannates(II) [BMIm][Sn$_{3}$Cl$_{7}$] and [BMIm][Sn$_{4}$4Br$_{9}$] are obtained by ionic-liquid-based synthesis with SnX$_{2}$ and [BMIm]X (X=Cl, Br; [BMIm]=1-butyl-3-methylimidazolium) near room temperature (45–50 °C). Both form colorless, moisture-sensitive crystals and exhibit layered anionic networks. [BMIm][Sn$_{3}$3Cl$_{7}$7] contains “horseshoe”-like $_{∞}$$^{1}$(SnCl$_{171}$Cl$_{2/2}$) chains that are linked via [SnCl$_{3}$]− anions to $_{∞}$$^{2}$[Sn$_{3}$Cl$_{7}$]− zigzag-planes. [BMIm][Sn$_{4}$Br$_{9}$] contains a complex $_{∞}$$^{2}$[Sn$_{4}$Br$_{9}$]− network with altogether four different crystallographic Sn$_{2+}$ sites and different coordination. For comparison with these complex halogenido stannates(II), PbCl$_{2}$/PbBr$_{2}$ are reacted with similar conditions, which, however, only results in [BMIm][PbCl$_{3}$] containing $_{∞}$$^{1}$[PbCl$_{3}$]− chains. Beside the crystal structures, the thermal and optical properties are examined and feature certain emission of visible light for all title compounds at room temperature. Whereas the quantum yields of [BMIm][Sn$_{4}$Br$_{9}$9] (3 %) and [BMIm][PbCl$_{3}$] (21 %) are low, [BMIm][Sn$_{3}$Cl$_{7}$] shows surprisingly efficient photoluminescence with a quantum yield of 46 %.